July 8, 2020 / 12:13 AM / a month ago

BRIEF-Telix Pharma Receives US FDA Feedback On Phase 3 Trial Design For Prostate Cancer Therapy Product

July 8 (Reuters) - Telix Pharmaceuticals Ltd:

* RECEIVES US FDA FEEDBACK ON PHASE 3 TRIAL DESIGN FOR PROSTATE CANCER THERAPY PRODUCT

* INTENDS TO FILE A PHASE 3 IND FOR TLX591 PRIOR TO END OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below